After 4 months of treatment with GSH, patients showed a significant decrease in ALT levels, as well as a decrease in triglyceride, non-esterified fatty acid and ferritin levels, suggesting a potential therapeutic effect of oral GSH in patients with NAFLD (Honda et al., 2017). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.